Kling Biotherapeutics

Pipeline

Built on insights from elite responders

Kling is developing a growing pipeline of drug candidates that recognize novel targets and epitopes. Our ability to identify functional antibodies and their targets is facilitated by a well-optimized process of target identification paired with experienced antibody engeneering to maximize the therapeutic potential of our discoveries.

Oncology Pipeline

Fully human antibodies derived from elite responders and engineered for optimal efficacy

Discovery
Lead Optimisation
Preclinical Development
Clinical Development

Infectious Diseases Pipeline

Stable B cell clones identified with Kling-Select and primed for directed evolution against emerging variants with Kling-Evolve

Discovery
Lead Optimisation
Preclinical Development
Clinical Development